A, Expression of SERPINA1F, WFDC15B and DEFB29 in mice on embryonic d 12 (E12), 13 (E13) and 16 (E16) and postnatal 10 wk in GDS2030/2031 (n = 2 per time point). B, Expression of SERPINA1F, WFDC15B and DEFB29 in postnatal C57BL/6 mice at 1, 4 and 8 wk of age in GDS4316 (n = 5 per time point). C, Expression of SERPINA1F and WFDC15B in hypertensive (HBP, n = 5), normotensive (NBP, n = 5) and hypotensive (LBP, n = 4) mice strain in GDS3675. D, Expression of WFDC15B in mice with null mutant GLIS family zinc finger 2 (GLIS2-/-) and wild type (WT) mice in GDS2817 (n = 3 per group). E, Expression of WFDC15B and DEFB29 in ureteric bud tips (UBT) and stalks (UBS) and metanephric mesenchyme (MM) from embryonic d 12 mice in GDS1583 (n = 2 per section). F, Expression of WFDC15B in mice with b-catenin overexpression (CTNNB1+) and WT mice on embryonic d 12 in GDS4449 (n = 3 per group). G, Expression of DEFB29 in homozygous mice for mutant methylmalonyl-CoA mutase (Mut-/-), heterozygous mice (Mut+/-) and WT mice in GDS4839 (n = 4 per group). H, Expression of DEFB29 in WT mice (n = 4), heterozygous mice (Cldn+/-, n = 3) and homozygous mice for mutant claudin 16 (Cldn-/-, n = 4) in GDS 3612. Each bar represents mean±SEM. Statistical difference is indicated by different letters (P<0.05) and ** (P<0.01) above the bars.